

Mohammad Faheem

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11093703/mohammad-faheem-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9
papers

147
citations

7
h-index

10
g-index

10
ext. papers

181
ext. citations

3.9
avg, IF

2.36
L-index

#	Paper	IF	Citations
9	Role of M.tuberculosis protein Rv2005c in the aminoglycosides resistance. <i>Microbial Pathogenesis</i> , 2019 , 132, 150-155	3.8	4
8	Mutation S115T in IMP-Type Metallo- β -Lactamases Compensates for Decreased Expression Levels Caused by Mutation S119G. <i>Biomolecules</i> , 2019 , 9,	5.9	2
7	Virtual Screening and Experimental Testing of B1 Metallo- β -Lactamase Inhibitors. <i>Journal of Chemical Information and Modeling</i> , 2018 , 58, 1902-1914	6.1	21
6	Proteomic analysis of a carbapenem-resistant <i>Klebsiella pneumoniae</i> strain in response to meropenem stress. <i>Journal of Global Antimicrobial Resistance</i> , 2017 , 8, 172-178	3.4	15
5	M. β -tuberculosis ferritin (Rv3841): Potential involvement in Amikacin (AK) & Kanamycin (KM) resistance. <i>Biochemical and Biophysical Research Communications</i> , 2016 , 478, 908-12	3.4	23
4	Cloning, Expression and Correlation of Rv0148 to Amikacin & Kanamycin Resistance. <i>Current Proteomics</i> , 2015 , 12, 96-100	0.7	14
3	Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria. <i>Journal of Biomolecular Structure and Dynamics</i> , 2014 , 32, 741-50	3.6	19
2	Evaluation of inhibitory action of novel non β -lactam inhibitor against <i>Klebsiella pneumoniae</i> carbapenemase (KPC-2). <i>PLoS ONE</i> , 2014 , 9, e108246	3.7	14
1	Biochemical characterization of CTX-M-15 from <i>Enterobacter cloacae</i> and designing a novel non- β -lactam- β -lactamase inhibitor. <i>PLoS ONE</i> , 2013 , 8, e56926	3.7	35